Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention

June 4, 2019

GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will join other vaccine industry leaders for a panel discussion at the 2019 BIO International Convention. Taking place in Philadelphia, Pennsylvania on Wednesday, June 5 at 11:00 a.m. EDT, the panel will cover the future of influenza vaccines, including regulatory process opportunities and challenges, real-world evidence, and investment costs and data that informs market uptake to help fulfill global health community goals for influenza prevention.

Details for the panel are as follows:

Title:	"The Future of Influenza Vaccines"
Date and Time:	Wednesday, June 5, 11:00 a.m.
Moderator:	Bruce Gellin, M.D., M.P.H., President, Global Immunization, Sabin Vaccine Institute
Panelists:	Mr. Trizzino Luciana Borio, Vice President, Technical Staff, In-Q-Tel Bruce D. Clark, Ph.D., Chief Executive Officer and President, Medicago, Inc. Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research (CBER) at Food an Gordon Naylor, President, Seqirus Paul Radspinner, President and Chief Executive Officer, FluGen Inc.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax' proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506